Trade PROK anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
ProKidney Corp. Class A (PROK) is trading at US$1.85, up 1.37% today as of Aug 28, 10:29 EDT. The company has a market capitalisation of US$336.37M. Over the past 52 weeks, PROK has traded between US$1.30 and US$3.48. On Syfe you can trade PROK with $0 commission and add it to your watchlist.
| Previous close | US$1.82 |
|---|---|
| Market cap | US$336.37M |
| 52-week range | US$1.30 – US$3.48 |
| Volume | 1.15M |
| Exchange | US |
Add to Watchlist
Set Price Alert
ProKidney Corp. Class A
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.
Year: 2022
ProKidney Names Greg Madison as Chief Commercial Officer
Mar 25, 8:40 PM · MT Newswires
ProKidney Corp. Class A (PROK) stock is trading at US$1.85, +1.37% from the previous close of US$1.82.
The market cap for ProKidney Corp. Class A (PROK) stock is approximately US$336.37M.
The 52-week high for ProKidney Corp. Class A (PROK) stock is US$3.48.
The 52-week low for ProKidney Corp. Class A (PROK) stock is US$1.30.
ProKidney Corp. Class A (PROK) does not currently pay a dividend.
Stay on top of PROK
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
